Skip to main navigation Skip to search Skip to main content

Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): Phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor

  • Seock Ah Im
  • , Sung Bae Kim
  • , Moon Hee Lee
  • , Young Hyuck Im
  • , Kyung Hee Lee
  • , Hong Suk Song
  • , Myung Ah Lee
  • , Junglim Lee
  • , Nam Su Lee
  • , Hae Sun Ham
  • , Tae You Kim
  • , Yeon Hee Park
  • , Kyung Eun Lee
  • , Kee Won Kim
  • , Jae Hong Seo
  • , Soon Nam Lee
  • , Young Seon Hong
  • , Yung Jue Bang
  • , Woo Kun Kim
  • , Hee Sook Park
  • Seoul National University

Research output: Contribution to journal › Article › peer-review

15   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): Phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science

Biochemistry, Genetics and Molecular Biology

Immunology and Microbiology